Ann Hematol

1. LOPEZ-FERNANDEZ E, de Linares-Fernandez S, Perez-Marfil MN, Vera-Goni JA, et al
   Correction to: Validation of the Spanish version of the EORTC QLQ-CML24 questionnaire for assessment of health-related quality of life in patients with chronic myeloid leukemia.
   Ann Hematol. 2025 Sep 5. doi: 10.1007/s00277-025-06603.
   

   >> Share

   
   
2. WANG Y, Zong W, Fan J, Rong L, et al
   Rapidly progressing after umbilical cord blood transplantation in a boy with acute myeloid leukemia with KAT6A::EP300 fusion transcript.
   Ann Hematol. 2025 Sep 2. doi: 10.1007/s00277-025-06573.
   

   >> Share

   
   
3. SANZ-SOLAS A, Saiz-Rodriguez M, Simal SC, Rodriguez-Veiga R, et al
   Comparative efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia treatment: a meta-analysis of clinical trials and Real-World outcomes.
   Ann Hematol. 2025 Aug 30. doi: 10.1007/s00277-025-06543.
   

   >> Share

   
   

   
   Blood

4. VENKATESH H, Granados Centeno E, Luo Q, Arroyo M, et al
   Leukemia escapes immunity by imposing a type 1 regulatory program on neoantigen-specific CD4+ T cells.
   Blood. 2025 Sep 4:blood.2024028194. doi: 10.1182/blood.2024028194.
   

   >> Share

   
   
5. PAPAPETROU EP
   Breaking ribosomes to fight leukemia.
   Blood. 2025;146:1155-1156.
   

   >> Share

   
   
6. REN H, Elliott N, Lye B, Sharif Shohan MU, et al
   Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia.
   Blood. 2025 Sep 3:blood.2025029302. doi: 10.1182/blood.2025029302.
   

   >> Share

   
   
7. DAMASKOU A, Wilson R, Gozdecka M, Giotopoulos G, et al
   Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.
   Blood. 2025;146:1239-1252.
   

   >> Share

   
   
8. GHOBADI A, Aldoss I, Maude SL, Bhojwani D, et al
   Phase 1/2 trial of anti-CD7 allogeneic WU-CART-007 for patients with relapsed/refractory T-cell malignancies.
   Blood. 2025;146:1163-1173.
   

   >> Share

   
   

   
   Bone Marrow Transplant

9. DACHY G, Labopin M, Socie G, Castilla-Llorente C, et al
   Impact of fludarabine dose on outcome after allo-HSCT with reduced intensity conditioning for older patients with AML.
   Bone Marrow Transplant. 2025;60:1258-1264.
   

   >> Share

   
   

   
   Br J Cancer

10. LAN Y, Deng J, He P, Huang W, et al
    Innovative rapid screening for complex BCR-ABL1 kinase domain mutations in TKI-treated leukaemia patients.
    Br J Cancer. 2025;133:674-684.
    

    >> Share

    
    

    
    Cancer Lett

11. POTTIER A, Park S, Lee Y, Liccardo F, et al
    TP53-Agnostic Lethality through Combined Pan-HDAC and CDK Inhibition in Acute Myeloid Leukemia.
    Cancer Lett. 2025 Sep 1:218011. doi: 10.1016/j.canlet.2025.218011.
    

    >> Share

    
    

    
    Eur J Haematol

12. LIEW-LITTORIN M, Deleskog-Spangberg L, Deneberg S, Janosi J, et al
    Second- and Third-Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML-A Population-Based Study.
    Eur J Haematol. 2025;115:423-432.
    

    >> Share

    
    

    
    Int J Hematol

13. TAKAHASHI H, Tanaka S, Yuza Y, Iijima-Yamashita Y, et al
    Safety and efficacy of arsenic trioxide in intensification therapy for newly diagnosed childhood acute promyelocytic leukemia: results from the JPLSG AML-P13 study.
    Int J Hematol. 2025 Sep 4. doi: 10.1007/s12185-025-04060.
    

    >> Share

    
    

    
    J Biol Chem

14. PARK JH, Chung KC
    Ubiquitin-specific protease 7 promotes the growth and oncogenic potential of acute myeloid leukemia cells through the deubiquitination and upregulation of LRRK2.
    J Biol Chem. 2025 Sep 2:110675. doi: 10.1016/j.jbc.2025.110675.
    

    >> Share

    
    
15. WANG H, Suh F, Fischietti M, Wray B, et al
    The ubiquitin ligase Triad1 influences myeloid leukemogenesis by regulating the integrated stress response.
    J Biol Chem. 2025;301:110484.
    

    >> Share

    
    
16. ALES E, Sackstein R
    Restricted human CD45 isoglycoforms serve as functional E-selectin ligands and delineate hematopoietic maturity.
    J Biol Chem. 2025;301:110431.
    

    >> Share

    
    

    
    Leuk Lymphoma

17. ABBASI-SHAHKOUH A, Rashidan K, Azadmehr A, Atashi A, et al
    Exploring the role of neutrophil extracellular traps in leukemia: a comprehensive review.
    Leuk Lymphoma. 2025 Sep 1:1-11. doi: 10.1080/10428194.2025.2547990.
    

    >> Share

    
    
18. BRAZEL D, Hermel DJ, Saven A
    Threading through the data for chemotherapy-free alternatives in the treatment of hairy cell leukemia.
    Leuk Lymphoma. 2025 Sep 1:1-8. doi: 10.1080/10428194.2025.2548373.
    

    >> Share

    
    
19. XU K, Mellios Z, Hyun J, Childerhouse A, et al
    Diagnosis and management of acute erythroid leukemia (AEL).
    Leuk Lymphoma. 2025 Sep 2:1-5. doi: 10.1080/10428194.2025.2553166.
    

    >> Share

    
    
20. SINGH L, Rastogi K, Singh A, Sathapathy S, et al
    Methods for the analysis of leukemic infiltration within cerebrospinal fluid in acute lymphoblastic leukemia-a systematic review.
    Leuk Lymphoma. 2025 Sep 5:1-13. doi: 10.1080/10428194.2025.2550580.
    

    >> Share

    
    

    
    Leuk Res

21. YANG Q, Ding Z, Liu Y, Chen S, et al
    Effect of sorafenib on prognosis in patients with low-allelic-ratio FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Res. 2025;157:108088.
    

    >> Share

    
    
22. MOLINA A, Khanna V, Jensen A, Stehr H, et al
    Molecular taxonomy of MDS/CMML patients influences responses to hypomethylating agents and clinical outcomes.
    Leuk Res. 2025;156:107736.
    

    >> Share

    
    

    
    Leukemia

23. GONG X, Liu W, Liu Y, Fang Q, et al
    Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial.
    Leukemia. 2025 Sep 5. doi: 10.1038/s41375-025-02696.
    

    >> Share

    
    
24. VENDITTI A, Hou JZ, Fenaux P, Jonas BA, et al
    Outcomes of patients treated with venetoclax plus azacitidine versus azacitidine alone stratified by advanced age and acute myeloid leukemia composite model.
    Leukemia. 2025 Sep 5. doi: 10.1038/s41375-025-02730.
    

    >> Share

    
    
25. MOCKING TR, Haaksma LH, Reuvekamp T, Kelder A, et al
    Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
    Leukemia. 2025 Sep 3. doi: 10.1038/s41375-025-02747.
    

    >> Share

    
    
26. XU G, Wang F, Chen M, Gao W, et al
    Targeting HDAC8 sensitizes tyrosine kinase inhibitors in the elimination of B-cell acute lymphoblastic leukemia cells through degradation of HIF-1alpha.
    Leukemia. 2025 Sep 2. doi: 10.1038/s41375-025-02749.
    

    >> Share

    
    
27. ALFONSO-PIEROLA A, Martinez-Cuadron D, Rodriguez-Veiga R, Gil C, et al
    Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.
    Leukemia. 2025 Sep 1. doi: 10.1038/s41375-025-02744.
    

    >> Share

    
    

    
    Oncol Rep

28. SUN J, Huang X, Zeng X, Lei Y, et al
    DBN1?mediated upregulation of GAB2 facilitates the migration and invasion of T?cell acute lymphoblastic leukemia cells.
    Oncol Rep. 2025;54:149.
    

    >> Share

    
    

    
    PLoS One

29. AMBAYYA A, Razali R, Sulong S, Yap YY, et al
    Gene expression profiling and pathway analysis in acute myeloid leukaemia-normal karyotype patients.
    PLoS One. 2025;20:e0328911.
    

    >> Share

    
    
30. PERGANTI F, Huybrechts I, Balduzzi AC, Barr R, et al
    Southern European Prospective Investigation Into Childhood Cancer and Nutrition (EPICkids): Study design and protocol.
    PLoS One. 2025;20:e0319110.
    

    >> Share

    
    
31. NI H, Shi Y, Wang M, Ji C, et al
    Analysis of global, regional, and national burden and attributable risk factors of acute lymphoblastic leukemia and acute myeloid leukemia from 1990 to 2021.
    PLoS One. 2025;20:e0330479.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

32. CHANG A, Pelletier AN, McGuire DJ, Tsagiopoulou M, et al
    PD-1 expression identifies proliferating malignant CLL B cells and is a potential biomarker of response to BTK inhibitor therapy.
    Proc Natl Acad Sci U S A. 2025;122:e2426935122.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share